VeriSim acquires drug discovery company Molomics Biotech

By The Science Advisory Board staff writers

May 12, 2022 -- VeriSim Life has acquired Molomics Biotech, a privately held drug discovery company that uses artificial intelligence (AI) technology to design more efficacious and safer therapeutics for an undisclosed amount.

The Barcelona-based firm incorporates AI with human collective intelligence to determine novel chemical structures with high therapeutic activity on diseases such as Parkinson's and levodopa-induced dyskinesia. The technology will integrate into VeriSim's virtual drug development engine, BioiSim, to further improve the success rates for the discovery, development, and approval of new drugs, the firms said.

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter